Home Publications Research Data Research Grants Equipment Inventions & Patents Awards Additional Research Activities Faculties & Institutions Research Areas

Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment

Biller BM, Casagrande A, Elenkova A, Boguszewski CL, Jallad RS, Hu B, Hubina E, Fazeli PK, Fleseriu M, Snyder PJ, Strasburger CJ, Bidlingmaier M, Zhao Y, Soares B, Trainer PJ, Struthers RS, Krasner A, Gadelha MR (2026)

---

Publication Type: Journal article

Publication year: 2026

Journal

Book Volume: 111

Pages Range: e1050-e1063

Journal Issue: 4

DOI: 10.1210/clinem/dgaf579

Abstract

Context Paltusotine is a nonpeptide, selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. Objective To evaluate efficacy and safety of paltusotine in patients with biochemically uncontrolled acromegaly not currently receiving medical therapy. Methods In this phase 3, randomized, double-blind, placebo-controlled trial, adults with medically untreated acromegaly at randomization (stratum 1: medication-naïve or off acromegaly medications ≥4 months [IGF-I ≥ 1.3 × upper limit of normal {ULN}]; stratum 2: controlled on a somatostatin receptor ligand and underwent washout [IGF-I increase ≥30% to ≥1.1 × ULN]) received paltusotine or placebo for 24 weeks. Results A total of 111 patients (stratum 1, n = 82; stratum 2, n = 29) enrolled (paltusotine, n = 54; placebo, n = 57). The primary endpoint of IGF-I normalization at 24 weeks was met in 55.6% of paltusotine-treated patients vs 5.3% for placebo (odds ratio [OR]: 42.81; 95% CI, 8.44-455.82; P <.0001), with superiority to placebo in both strata. Paltusotine treatment decreased IGF-I in 92.6% of patients within the first 4 weeks. All secondary endpoints were met: mean (±SE) change in IGF-I of -0.82 ± 0.08×ULN with paltusotine vs 0.09 ± 0.08×ULN with placebo (P <.0001); IGF-I < 1.3×ULN in 66.7% vs 14.0% of patients (OR: 18.32; 95% CI, 5.64-79.16; P <.0001); GH (5-sample mean) < 1.0 ng/mL in 57.4% vs 17.5% (OR: 7.59; 95% CI, 2.78-23.48; P <.0001); mean (±SE) change in Acromegaly Symptom Diary score of -2.7 ± 1.4 vs 2.8 ± 1.4 (P =.004). Most adverse events were acromegaly symptoms or mild, transitory gastrointestinal effects characteristic of somatostatin receptor ligands (eg, diarrhea, abdominal pain). Pituitary tumor volume was stable or reduced in paltusotine-treated patients. Conclusion IGF-I normalized in significantly more patients with uncontrolled acromegaly treated with paltusotine vs placebo. Paltusotine was associated with rapid, sustained IGF-I reduction, significant symptom improvement and stable or reduced pituitary tumor size and was well tolerated.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Biller, B.M., Casagrande, A., Elenkova, A., Boguszewski, C.L., Jallad, R.S., Hu, B.,... Gadelha, M.R. (2026). Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. Journal of Clinical Endocrinology and Metabolism, 111(4), e1050-e1063. https://doi.org/10.1210/clinem/dgaf579

MLA:

Biller, Beverly M.K., et al. "Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment." Journal of Clinical Endocrinology and Metabolism 111.4 (2026): e1050-e1063.

BibTeX: Download